Satellos Bioscience Inc.

Satellos Bioscience Initiates Phase 1 Trial of SAT-3247 for Duchenne Muscular Dystrophy

- Satellos Bioscience has dosed the first healthy volunteer in a Phase 1 clinical study of SAT-3247, an oral small molecule drug targeting AAK1. - The Phase 1 trial includes healthy volunteers to assess safety and pharmacokinetics, with initial data expected in Q4 2024. - A second component of the study, involving adult Duchenne muscular dystrophy (DMD) patients, is anticipated to begin in Q1 2025. - SAT-3247 aims to regenerate skeletal muscle in DMD patients, independent of dystrophin and genetic mutation status.